Renal cell carcinoma, central nervous system (CNS) tumors, pheochromocytoma, retinal tumors, and pancreatic neuroendocrine tumors may all be identified individually, but when should you suspect von Hippel-Lindau (VHL) disease? VHL disease is a rare disorder characterized by the development of benign and malignant tumors and cysts in numerous organs/systems. The rarity of VHL disease and limited awareness of its clinical signs, symptoms, and diagnostic workup often results in delayed diagnosis. Given the need for early intervention, this delay contributes to less than optimal patient outcomes. Through this interactive Clinical Case Challenge, follow a real-world patient case, get instant feedback on answers to clinically relevant questions, and access downloadable evidence and relevant clinical practice tips. You can also see how you stack up against the knowledge of fellow healthcare providers!
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/advancing-diagnosis-evidence-based-care-von-hippel-lindau-disease-micro
- Start Date: 2024-02-29 06:00:00
- End Date: 2024-02-29 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - MOC Credit Details: ABIM - 0.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Merck (Any division) - Amount: 33166.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology